An Alzheimer’s treatment from AC Immune and Genentech posted mixed results in a midstage study, missing its coprimary endpoints but performing well in patients with milder symptoms. That leaves Roche, Genentech’s parent company, with a big decision to make on whether to take the plunge into Phase III.

…read more

Source: Roche is at an Alzheimer’s crossroads after mixed data for AC Immune’s drug


0 No comments